Navigation Links
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
Date:4/22/2013

EXTON, Pa., April 22, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections (CDI). CDI is a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications. VP20621 contains the spores of a naturally occurring non-toxin producing strain of C. difficile. 

In this study of 168 patients who were randomized and dosed following antibiotic treatment for CDI, VP20621 was well tolerated, with mild-moderate headache the only notable associated adverse event reported by 10 percent of subjects compared to 2 percent on placebo. Viable non-toxigenic C. difficile was detected in stool culture (the primary endpoint of the study) in 54 percent of subjects treated with the low dose of VP20621 and up to 79 percent of those receiving the high dose. In addition, across all dose groups, VP20621 reduced the incidence of CDI recurrence (a secondary endpoint of the study) by greater than or equal to 50 percent vs. placebo, with a similar reduction in antibacterial treatment for CDI vs. placebo in this study. The CDI recurrence rate was two percent (2/86) in the subgroup of patients successfully colonized with VP20621.

"These data demonstrate that colonization with VP20621 was achieved in the majority of patients, and that in these patients, 98 percent had no recurrence of C. difficile infection," commented Dr. Colin Broom , ViroPharma's chief scientific officer. "We have long known that colonization of su
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/19/2014)... 2014 BCC Research reveals in its ... MARKETS , the global market for human antifungal therapeutics ... 2018, with a five-year compound annual growth rate (CAGR) ... at a steady 3.8% CAGR. , Given the current ... coupled with the incidence of increasing mortality and the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Ticket Down ... tickets for her 2015 “Honeymoon” Tour. This popular ... for additional savings at the checkout. , Ariana Grande 2015 ... (Independence Event Center) , Feb. 28, 2015: Milwaukee, WI (BMO ... (Xcel Energy Center) , March 03, 2015: Chicago, IL (Allstate ...
(Date:9/19/2014)... An ultrasensitive biosensor made from the wonder material graphene ... increased risk of developing cancer. , The biosensor ... more sensitive than bioassay tests currently in use, and ... minutes, opening up the possibility of a rapid, point-of-care ... presented today, 19 September, in IOP Publishing,s journal ...
(Date:9/19/2014)... Follow us on LinkedIn ... detection and quantification of the presence of antigens ... steady expansion in immunodiagnostics and technological advancements in ... market has evolved remarkably well over the years. ... cardio-vascular ailments, infectious diseases, allergy and cancer, continue ...
(Date:9/19/2014)... 19, 2014 Recent financial data ... industry increased their sales by 7% in the last ... trucking industry can be used as a bellwether to ... whole. This data has been proven to show trends ... freight transportation. Other non-trucking data is largely influenced by ...
Breaking Medicine News(10 mins):Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Graphene sensor tracks down cancer biomarkers 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... Institute along with the Hong Kong Cleft Lip and Palate ... for congenital facial deformities in the city of Chennai//. The ... Samman, Director of the Hong Kong Cleft Lip & Palate ... Surgeons. , ,The center has tied up with Hong ...
... the 'Bambach Saddle Seat' invented by Australian therapist Mary Gale, ... ,The chair, which is priced at 399 pounds, was found ... positions the pelvis correctly. ,Each person tested was ... backwards slightly and given a task to perform. This was ...
... blamed for obesity by a study in Florida. The study was ... fructose present in fruits//, honey and other natural sources might be ... that Fructose makes beleive that the subject is hungrier than actually ... ,The study in animals have revealed that fructose has a ...
... persistent pain may be increased by an inflamed injury, according ... even after it has disappeared//. Several million Canadians are reported ... has published the study. The NR2B proteins in mice are ... to imprint upon the brain a painful response even when ...
... 2025, the number of people in Britain over the age ... pensions and pensioner spending power will increase. Answers to problems//, ... ,In a move to address the issues of ageing ... our lives, the Economic and Social Research Council (ESRC) is ...
... ,The disabled, homeless man who died on ... sub-zero temperatures had refused the help of paramedics, say ... the paramedics on Saturday night did actually respond to ... and the patient clearly refused any assistance from the ...
Cached Medicine News:Health News:New Chair Invented To Relieve Backache 2Health News:Fructose is a tricker and not all that sweet! 2Health News:ESRC offers new dynamics for old in UK 2Health News:ESRC offers new dynamics for old in UK 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: